China-based Haisco Pharmaceutical Group has entered a licensing and research collaboration with Eli Lilly and Company to discover and develop innovative medicines across multiple therapeutic areas.

• Collaboration structure: Haisco will identify and discover up to five innovative target programmes, while Eli Lilly will lead IND-enabling studies, clinical development, and commercialisation.
• Rights: Eli Lilly will receive exclusive worldwide rights for certain programmes and exclusive rights outside mainland China, Hong Kong, Macau, and Taiwan for certain other programmes.
• Research focus: The collaboration will cover programmes discovered through Haisco’s internal drug discovery capabilities.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.